Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C. Al Tabaa Y, et al. Among authors: morschhauser f. Blood Adv. 2023 Jul 25;7(14):3735-3738. doi: 10.1182/bloodadvances.2023009911. Blood Adv. 2023. PMID: 37067945 Free PMC article. No abstract available.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C, Kraeber-Bodéré F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D. Bodet-Milin C, et al. Among authors: morschhauser f. Haematologica. 2008 Mar;93(3):390-7. doi: 10.3324/haematol.10591. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268287 Free article. Clinical Trial.
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Ribrag V, et al. Among authors: morschhauser f. Blood. 2009 Apr 2;113(14):3307-13. doi: 10.1182/blood-2008-03-148874. Epub 2008 Sep 3. Blood. 2009. PMID: 18768784 Free article.
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup. Jaccard A, et al. Among authors: morschhauser f. Blood. 2011 Feb 10;117(6):1834-9. doi: 10.1182/blood-2010-09-307454. Epub 2010 Dec 1. Blood. 2011. PMID: 21123825 Free article. Clinical Trial.
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. Decaudin D, et al. Among authors: morschhauser f. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8. doi: 10.1016/j.clml.2011.03.007. Epub 2011 Apr 9. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575926 Clinical Trial.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Récher C, et al. Among authors: morschhauser f. Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4. Lancet. 2011. PMID: 22118442 Free article. Clinical Trial.
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Salles G, et al. Among authors: morschhauser f. Blood. 2012 May 31;119(22):5126-32. doi: 10.1182/blood-2012-01-404368. Epub 2012 Mar 19. Blood. 2012. PMID: 22431570 Free article. Clinical Trial.
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Ghesquières H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, Malphettes M, Clément L, Ferlay C, Brice P. Ghesquières H, et al. Among authors: morschhauser f. Leuk Lymphoma. 2013 Nov;54(11):2399-404. doi: 10.3109/10428194.2013.776165. Epub 2013 Mar 13. Leuk Lymphoma. 2013. PMID: 23410099
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Bachy E, et al. Among authors: morschhauser f. Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3. Haematologica. 2013. PMID: 23645690 Free PMC article. Clinical Trial.
325 results